Humabs BioMed, a subsidiary of Vir Biotechnology is a leading Swiss antibody therapeutics company that discovers and develops superior antibodies directly derived from individuals who have successfully overcome major diseases.
Via dei Gaggini 3, 6500 Bellinzona, Switzerland
Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.
Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM1 antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1-CEACAM mediated check-point blockade.